RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - October 30, 2007) - Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced with its collaborative partner, the International Childhood Liver Tumour Strategy Group (known as SIOPEL), a multi-disciplinary group of specialists under the umbrella of the International Society of Pediatric Oncology (SIOP), that the planned Phase III trial of sodium thiosulfate (STS) in children with hepatoblastoma (liver cancer) has opened for patient enrollment in the United Kingdom, with SIOPEL centers in up to 33 further countries also expected to participate following the international launch of the trial at a SIOPEL meeting in Mumbai, India today.
